Skip to main content

Advertisement

ADVERTISEMENT

News

Renal denervation
10/29/2024
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step...
10/29/2024
Cath Lab Digest
EMPOWER CAD Completed Enrollment
Intravascular Lithotripsy
10/28/2024
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to...
10/28/2024
Cath Lab Digest
aortic valve stenosis
10/28/2024
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused...
10/28/2024
Cath Lab Digest

Advertisement

Pulmonary Embolism
10/28/2024
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular...
10/28/2024
Cath Lab Digest
EARLY TAVR
10/28/2024
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients...
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients...
With a median follow up of 3.8...
10/28/2024
Cath Lab Digest
The pivotal investigational device exemption (IDE) study, which enrolled 256 patients at 18 sites in the US, met the primary endpoint. MACCE (Major Adverse Cardiac and Cerebrovascular Events) rate at 30 days was 6.3%, significantly below the pre-defined performance goal (see figure 1).
Mechanical Circulatory Support
10/28/2024
The pivotal investigational device exemption (IDE) study, which enrolled 256 patients at 18 sites in the US, met the primary endpoint. MACCE (Major Adverse Cardiac and Cerebrovascular Events) rate at 30 days was 6.3%, significantly below the...
The pivotal investigational device exemption (IDE) study, which enrolled 256 patients at 18 sites in the US, met the primary endpoint. MACCE (Major Adverse Cardiac and Cerebrovascular Events) rate at 30 days was 6.3%, significantly below the...
The pivotal investigational...
10/28/2024
Cath Lab Digest

Advertisement

Drug-Coated Balloons
10/28/2024
First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase   Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA...
First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase   Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA...
First-of-its-kind Dual-Drug...
10/28/2024
Vascular Disease Management
Physiology
10/28/2024
The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoint and revealed significant economic and resource utilization...
The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoint and revealed significant economic and resource utilization...
The investigators shared the...
10/28/2024
Cath Lab Digest
radial access
10/28/2024
The Armery solution maximizes support and protection during radial procedures, and furthers Rampart’s mission to provide radiation protection solutions for healthcare teams delivering care in interventional suites. 
The Armery solution maximizes support and protection during radial procedures, and furthers Rampart’s mission to provide radiation protection solutions for healthcare teams delivering care in interventional suites. 
The Armery solution maximizes...
10/28/2024
Cath Lab Digest

Advertisement

coronary sinus reduction
10/27/2024
The A-FLUX Reducer System is engineered with SwiftCell Technology™, a small-cell proprietary design based on computational modeling, to redistribute oxygen supply to the sub-endocardium layer of the heart muscle.
The A-FLUX Reducer System is engineered with SwiftCell Technology™, a small-cell proprietary design based on computational modeling, to redistribute oxygen supply to the sub-endocardium layer of the heart muscle.
The A-FLUX Reducer System is...
10/27/2024
Cath Lab Digest

Advertisement